8 Feb 2008: An extraordinary general meeting of NorDiag ASA was held on 8 February 2008 at 10:00 hours. All proposals of the Board set out in the Notice were unanimously approved by the votes cast and the share capital represented on the general meeting.

The minutes from the annual general meeting will be available on www.newsweb.no and www.nordiag.com.

Ann-Kristin Hageløkken is elected as a new member of the Board of directors on todays extraordinary general meeting. She is general manager of the seed money fund Biovekst AS and CEO of Bioparken AS. She has more than 25 years of experience from product-/business development and marketing within the banking/telecommunication sector and the biotechnology industry, the last 15 years on managerial level. Hageløkken is a bioengineer from Oslo University College, and holds a business degree and a Master of Management from BI.

Contact:
CEO Mårten Wigstøl, +47 911 65775

About NorDiag ASA:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. NorDiag has also launched a product for diagnostic of sexual transmitted infectious. In addition, the company has other applications for early diagnosis of cancer under development, as well as applications for other infectious diseases in the product pipeline. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. www.nordiag.com